Spots Global Cancer Trial Database for A Study Of The Selective PKC-β Inhibitor MS- 553
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Of The Selective PKC-β Inhibitor MS- 553
Official Title: A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study ID: NCT03492125
Study Description
Brief Summary: A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
The Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, United States
MD Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
